|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Dicker D, Pain A, Hamavid H,
Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et
al: The global burden of cancer. JAMA Oncol. 1:505–527. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lordick F, Lorenzen S, Yamada Y and Ilson
D: Optimal chemotherapy for advanced gastric cancer: Is there a
global consensus? Gastric Cancer. 17:213–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim C, Mulder K and Spratlin J: How
prognostic and predictive biomarkers are transforming our
understanding and management of advanced gastric cancer.
Oncologist. 19:1046–1055. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kumar R, Gururaj AE and Barnes CJ:
p21-activated kinases in cancer. Nat Rev Cancer. 6:459–471. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ye DZ and Field J: PAK signaling in
cancer. Cell Logist. 2:105–116. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wells CM and Jones GE: The emerging
importance of group II PAKs. Biochem J. 425:465–473. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fang ZP, Jiang BG, Gu XF, Zhao B, Ge RL
and Zhang FB: P21-activated kinase 5 plays essential roles in the
proliferation and tumorigenicity of human hepatocellular carcinoma.
Acta Pharmacol Sin. 35:82–88. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao ZS and Manser E: PAK and other
Rho-associated kinases-effectors with surprisingly diverse
mechanisms of regulation. Biochem J. 386:201–214. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pandey A, Dan I, Kristiansen TZ, Watanabe
NM, Voldby J, Kajikawa E, Khosravi-Far R, Blagoev B and Mann M:
Cloning and characterization of PAK5, a novel member of mammalian
p21-activated kinase-II subfamily that is predominantly expressed
in brain. Oncogene. 21:3939–3948. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kobayashi K, Inokuchi M, Takagi Y, Otsuki
S, Fujimori Y, Sato Y, Yanaka Y, Higuchi K, Aburatani T, Tomii C,
et al: Prognostic significance of PAK4 expression in gastric
cancer. J Clin Pathol. 69:580–585. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Giroux V, Iovanna J and Dagorn JC: Probing
the human kinome for kinases involved in pancreatic cancer cell
survival and gemcitabine resistance. FASEB J. 20:1982–1991. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gong W, An Z, Wang Y, Pan X, Fang W, Jiang
B and Zhang H: P21-activated kinase 5 is overexpressed during
colorectal cancer progression and regulates colorectal carcinoma
cell adhesion and migration. Int J Cancer. 125:548–555. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gu J, Li K, Li M, Wu X, Zhang L, Ding Q,
Wu W, Yang J, Mu J, Wen H, et al: A role for p21-activated kinase 7
in the development of gastric cancer. FEBS J. 280:46–55. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gu X, Wang C, Wang X, Ma G, Li Y, Cui L,
Chen Y, Zhao B and Li K: Efficient inhibition of human glioma
development by RNA interference-mediated silencing of PAK5. Int J
Biol Sci. 11:230–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Japanese Gastric Cancer Association, .
Japanese classification of gastric carcinoma. (3rd English).
Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
International Union Against Cancer (UICC),
. TNM classification of malignant tumors. Sobin LH, Gospodarowicz
MK and Wittekind C: 7th. Wiley-Blackwell; Oxford: 2009
|
|
17
|
Dan C, Nath N, Liberto M and Minden A:
PAK5, a new brain-specific kinase, promotes neurite outgrowth in
N1E-115 cells. Mol Cell Biol. 22:567–577. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Timm T, Matenia D, Li XY, Griesshaber B
and Mandelkow EM: Signaling from MARK to tau: Regulation,
cytoskeletal crosstalk, and pathological phosphorylation.
Neurodegener Dis. 3:207–217. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu X and Frost JA: Multiple Rho proteins
regulate the subcellular targeting of PAK5. Biochem Biophys Res
Commun. 351:328–335. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cotteret S, Jaffer ZM, Beeser A and
Chernoff J: p21-activated kinase 5 (Pak5) localizes to mitochondria
and inhibits apoptosis by phosphorylating BAD. Mol Cell Biol.
23:5526–5539. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cotteret S and Chernoff J:
Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic
properties. Mol Cell Biol. 26:3215–3230. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bang YJ, van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gravalos C and Jimeno A: HER2 in gastric
cancer: A new prognostic factor and a novel therapeutic target. Ann
Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hofmann M, Stoss O, Shi D, Büttner R, van
de Vijver M, Kim W, Ochiai A, Rüschoff J and Henkel T: Assessment
of a HER2 scoring system for gastric cancer: Results from a
validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Radu M, Semenova G, Kosoff R and Chernoff
J: PAK signalling during the development and progression of cancer.
Nat Rev Cancer. 14:13–25. 2014. View
Article : Google Scholar : PubMed/NCBI
|
